title: [Anti-VEGF: one drug for different conditions?].
authors.forename: S Y
authors.initials: SY
authors.lastname: Cohen
authors.forename: P
authors.initials: P
authors.lastname: Massin
authors.forename: E
authors.initials: E
authors.lastname: Souied
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy; D058492:Drug Repositioning; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy; D011379:Prognosis; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab